Department of Nuclear Medicine, Peking University First Hospital, No. 8, Xishiku St., West District, Beijing, 100034, China.
Department of Radiation Oncology, Peking University First Hospital, Beijing, 100034, China.
BMC Med Imaging. 2023 Apr 5;23(1):49. doi: 10.1186/s12880-023-01004-7.
To explore valuable predictors for mediastinal lymph node metastasis in non-small cell lung cancer (NSCLC) patients, we analyzed the potential roles of standardized uptake value (SUV)-derived parameters from preoperative F-FDG PET/CT combined with clinical characteristics.
Data from 224 NSCLC patients who underwent preoperative F-FDG PET/CT scans in our hospital were collected. Then, a series of clinical parameters including SUV-derived features [SUVmax of mediastinal lymph node and primary-tumor SUVmax, SUVpeak, SUVmean, metabolic tumor volume (MTV) and total lesion glycolysis (TLG)] were evaluated. The best possible cutoff points for all measuring parameters were calculated using receiver operating characteristic curve (ROC) analysis. Predictive analyses were performed using a Logistic regression model to determine the predictive factors for mediastinal lymph node metastasis in NSCLC and lung adenocarcinoma patients. After multivariate model construction, data of another 100 NSCLC patients were recorded. Then, 224 patients and 100 patients were enrolled to validate the predictive model by the area under the receiver operating characteristic curve (AUC).
The mediastinal lymph node metastasis rates in 224 patients for model construction and 100 patients for model validation were 24.1% (54/224) and 25% (25/100), respectively. It was found that SUVmax of mediastinal lymph node ≥ 2.49, primary-tumor SUVmax ≥ 4.11, primary-tumor SUVpeak ≥ 2.92, primary-tumor SUVmean ≥ 2.39, primary-tumor MTV ≥ 30.88 cm, and primary-tumor TLG ≥ 83.53 were more prone to mediastinal lymph node metastasis through univariate logistic regression analyses. The multivariate logistic regression analyses showed that the SUVmax of mediastinal lymph nodes (≥ 2.49: OR 7.215, 95% CI 3.326-15.649), primary-tumor SUVpeak (≥ 2.92: OR 5.717, 95% CI 2.094-15.605), CEA (≥ 3.94 ng/ml: OR 2.467, 95% CI 1.182-5.149), and SCC (< 1.15 ng/ml: OR 4.795, 95% CI 2.019-11.388) were independent predictive factors for lymph node metastasis in the mediastinum. It was found that SUVmax of the mediastinal lymph node (≥ 2.49: OR 8.067, 95% CI 3.193-20.383), primary-tumor SUVpeak (≥ 2.92: OR 9.219, 95% CI 3.096-27.452), and CA19-9 (≥ 16.6 U/ml: OR 3.750, 95% CI 1.485-9.470) were significant predictive factors for mediastinal lymph node metastasis in lung adenocarcinoma patients. The AUCs for the predictive value of the NSCLC multivariate model through internal and external validation were 0.833 (95% CI 0.769- 0.896) and 0.811 (95% CI 0.712-0.911), respectively.
High SUV-derived parameters (SUVmax of mediastinal lymph node and primary-tumor SUVmax, SUVpeak, SUVmean, MTV and TLG) might provide varying degrees of predictive value for mediastinal lymph node metastasis in NSCLC patients. In particular, the SUVmax of mediastinal lymph nodes and primary-tumor SUVpeak could be independently and significantly associated with mediastinal lymph node metastasis in NSCLC and lung adenocarcinoma patients. Internal and external validation confirmed that the pretherapeutic SUVmax of the mediastinal lymph node and primary-tumor SUVpeak combined with serum CEA and SCC can effectively predict mediastinal lymph node metastasis of NSCLC patients.
通过分析术前 F-FDG PET/CT 获得的标准化摄取值(SUV)衍生参数与临床特征的关系,探讨非小细胞肺癌(NSCLC)患者纵隔淋巴结转移的有价值预测因子。
收集我院 224 例 NSCLC 患者术前 F-FDG PET/CT 检查资料,评估包括纵隔淋巴结 SUVmax 和原发灶 SUVmax、SUVpeak、SUVmean、代谢肿瘤体积(MTV)和总病灶糖酵解(TLG)在内的一系列临床参数。采用受试者工作特征曲线(ROC)分析计算所有测量参数的最佳可能截断点。使用 Logistic 回归模型进行预测分析,确定 NSCLC 和肺腺癌患者纵隔淋巴结转移的预测因素。建立多变量模型后,记录另外 100 例 NSCLC 患者的数据。然后,使用 224 例患者和 100 例患者的 AUC 验证预测模型。
224 例患者用于模型构建,100 例患者用于模型验证,纵隔淋巴结转移率分别为 24.1%(54/224)和 25%(25/100)。单因素 logistic 回归分析发现,纵隔淋巴结 SUVmax≥2.49、原发灶 SUVmax≥4.11、原发灶 SUVpeak≥2.92、原发灶 SUVmean≥2.39、原发灶 MTV≥30.88 cm3 和原发灶 TLG≥83.53 更易发生纵隔淋巴结转移。多因素 logistic 回归分析显示,纵隔淋巴结 SUVmax(≥2.49:OR 7.215,95%CI 3.326-15.649)、原发灶 SUVpeak(≥2.92:OR 5.717,95%CI 2.094-15.605)、CEA(≥3.94ng/ml:OR 2.467,95%CI 1.182-5.149)和 SCC(<1.15ng/ml:OR 4.795,95%CI 2.019-11.388)是纵隔淋巴结转移的独立预测因素。进一步分析发现,纵隔淋巴结 SUVmax(≥2.49:OR 8.067,95%CI 3.193-20.383)、原发灶 SUVpeak(≥2.92:OR 9.219,95%CI 3.096-27.452)和 CA19-9(≥16.6U/ml:OR 3.750,95%CI 1.485-9.470)是肺腺癌患者纵隔淋巴结转移的显著预测因素。内部和外部验证的 NSCLC 多变量模型预测价值的 AUC 分别为 0.833(95%CI 0.769-0.896)和 0.811(95%CI 0.712-0.911)。
高 SUV 衍生参数(纵隔淋巴结和原发灶 SUVmax、SUVpeak、SUVmean、MTV 和 TLG)可能为 NSCLC 患者纵隔淋巴结转移提供不同程度的预测价值。特别是纵隔淋巴结 SUVmax 和原发灶 SUVpeak 可独立且显著与 NSCLC 和肺腺癌患者的纵隔淋巴结转移相关。内部和外部验证证实,术前纵隔淋巴结 SUVmax 和原发灶 SUVpeak 联合血清 CEA 和 SCC 可有效预测 NSCLC 患者的纵隔淋巴结转移。